Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura

Summary

Thrombotic thrombocytopenic purpura (TTP) is characterised by the deficiency of the von Willebrand factor (VWF) cleaving protease (ADAMTS-13). Although several observations indicate an important role of endothelial activation in the pathogenesis of TTP, no reliable endothelial activation markers are available in the clinical management of TTP. Our aim was to investigate the presence of endothelial activation in TTP and to determine its connections with disease activity, therapy and complement activation. We enrolled 54 patients (median age 40.5; 44 females) and 57 healthy controls (median age 34; 30 females),VWF antigen, carboxiterminal-pro-endothelin-1 (CT-proET-1), complement Factor H and complement activation products (C3bBbP and SC5b-9) were measured. In both the acute and remission phase of TTP we found increased CT-proET-1 and VWF levels, while Factor H levels decreased compared with healthy controls. In remission, however, the elevated CT-proET-1 levels showed 22 % decrease when compared with the acute phase in paired samples (p=0.0031), whereas no changes for VWF and Factor H levels were observed. We also found positive correlations between CT-proET-1 levels and alternative pathway activation markers (C3bBbP; p=0.0360; r=0.4299). The data we present here demonstrate a role of endothelium activation in patients with acute TTP. The finding that CT-proET-1 levels decreased in remission compared with the acute phase further supports endothelial involvement. In addition, we show that endothelial activation also correlated with the activation of the alternative complement pathway. The data suggest that complement and endothelium activation jointly contribute to the development of TTP episodes in patients with predisposition to TTP.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

TTP - endothelial cell - endothelin-1 - ADAMTS13 deficiency - complement activation

• References

• 1 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
• 2 Furlan M, Robles R, Galbusera M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
• 3 Sadler JE. Biochemistry and genetics of von Willebrand factor. Ann Rev Biochem 1998; 67: 395-424.
• 4 Verweij CL. Biosynthesis of human von Willebrand factor. Haemostasis 1988; 18: 224-245.
• 5 Ribes JA, Francis CW. Multimer size dependence of von Willebrand factor binding to crosslinked or noncrosslinked fibrin. Blood 1990; 75: 1460-1465.
• 6 Stufano F, LAM S, Pontiggia S. et al. von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 728-730.
• 7 Ruiz-Torres MP, Casiraghi F, Galbusera M. et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93: 443-452.
• 8 Jimenez JJ, Jy W, Mauro LM. et al. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 2003; 123: 896-902.
• 9 Mori Y, Wada H, Okugawa Y. et al. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Clin Appl Thromb Hemost 2001; 7: 5-9.
• 10 Kohan DE, Rossi NF, Inscho EW. et al. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011; 91: 1-77.
• 11 Burke GW, Ciancio G, Cirocco R. et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. Transplantation 1999; 68: 1336-1342.
• 12 Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PloS one 2013; 8: e59372.
• 13 Rosove MH. Thrombotic microangiopathies. Semin Arthr Rheum 2014; 43: 797-805.
• 14 Kahaleh MB, Fan PS. Effect of cytokines on the production of endothelin by endothelial cells. Clin Exp Rheum 1997; 15: 163-167.
• 15 Reti M, Farkas P, Csuka D. et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 791-798.
• 16 Papassotiriou J, Morgenthaler NG, Struck J. et al. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 2006; 52: 1144-1151.
• 17 Struck J, Morgenthaler NG, Bergmann A. Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides 2005; 26: 2482-2486.
• 18 Gombos T, Mako V, Cervenak L. et al. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost 2009; 102: 573-580.
• 19 Cat R, Rosario NA, de Messias IT. et al. Evaluation of complement activation in premature newborn infants with hyaline membrane disease. Eur J Ped 1993; 152: 205-208.
• 20 Csuka D, Fust G, Farkas H. et al. Parameters of the classical complement pathway predict disease severity in hereditary angioedema. Clin Immunol 2011; 139: 85-93.
• 21 Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982; 28: 1356-1358.
• 22 Jenkins PV, O’Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. Transfusion 2006; 46: 1836-1844.
• 23 Westwood JP, Langley K, Heelas E. et al. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol 2014; 164: 858-866.
• 24 Rayes J, Roumenina LT, Dimitrov JD. et al. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 2014; 123: 121-125.
• 25 Feng S, Liang X, Cruz MA. et al. The interaction between factor H and Von Willebrand factor. PLoS One 2013; 8: e73715.
• 26 Stahl AL, Vaziri-Sani F, Heinen S. et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008; 111: 5307-5315.
• 27 Tedesco F, Pausa M, Nardon E. et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185: 1619-1627.
• 28 Fang W, Guo ZH, Zhang BQ. et al. Effect of C5a on expression of thrombomodulin in endothelial cells in vitro. Chin Crit Care Med 2009; 21: 168-171.
• 29 Van de Wouwer M, Plaisance S, De Vriese A. et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006; 4: 1813-1824.
• 30 Delvaeye M, Noris M, De Vriese A. et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345-357.
• 31 Tati R, Kristoffersson AC, Stahl AL. et al. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 2013; 191: 2184-2193.
• 32 Schuetz P, Christ-Crain M, Morgenthaler NG. et al. Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 2007; 14: 345-351.
• 33 Gombos T, Forhecz Z, Pozsonyi Z. et al. Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure. Inflam Res 2009; 58: 298-305.
• 34 Jankowska EA, Filippatos GS, von Haehling S. et al. Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. PloS one 2011; 6: e14506.
• 35 Silva Marques J, Martins SR, Calisto C. et al. An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: emerging role of CT-proET-1. J Heart Lung Transplant 2013; 32: 1214-1221.
• 36 Zuber J, Fakhouri F, Roumenina LT. et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Rev Nephrol 2012; 8: 643-657.
• 37 Wada H, Kaneko T, Ohiwa M. et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol 1993; 44: 101-105.
• 38 Wada H, Kaneko T, Ohiwa M. et al. Plasma cytokine levels in thrombotic thrombocytopenic purpura. Am J Hematol 1992; 40: 167-170.
• 39 Emori T, Hirata Y, Imai T. et al. Cellular mechanism of thrombin on endothelin- 1 biosynthesis and release in bovine endothelial cell. Biochem Pharmacol 1992; 44: 2409-2411.
• 40 Yang LL, Arab S, Liu P. et al. The role of endothelin-1 in myocarditis and inflammatory cardiomyopathy: old lessons and new insights. Canad J Physiol Pharmacol 2005; 83: 47-62.
• 41 Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol 1992; 262: C854-C861.